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Background Positron emission tomography (PET) scan
is emerging as a promising imaging technique to detect
large-vessel inﬂammation in giant cell arteritis (GCA).
However, the lack of a standardised deﬁnition of arteritis
based on 18ﬂuorodeoxyglucose (FDG) uptake is an
important limitation to the use of PET scan for diagnostic
purposes.
Objective To prospectively assess the intensity and
distribution of FDG uptake at different vascular territories
in patients with newly diagnosed GCA compared with
controls.
Methods 32 consecutive, biopsy-proven, GCA patients
treated with glucocorticoids for ≤3 days were included.
The control group consisted of 20 individuals, who
underwent PET/CT for cancer staging. Maximal
standardised uptake value (SUVm) was calculated at four
aortic segments, supraaortic branches and iliac-femoral
territory. Sensitivity and speciﬁcity was calculated by
receiver–operator characteristic curves (ROC) analysis.
Results Mean SUVm was signiﬁcantly higher in patients
than in controls in all vessels explored and correlated with
acute-phase reactants and serum IL-6. Mean of the SUVm
at all the vascular territories had an area under the curve
(AUC) of 0.830, and a cut-off of 1.89 yielded a sensitivity
of 80% and a speciﬁcity of 79% for GCA diagnosis.
There were no signiﬁcant differences in AUC among the
vascular beds examined.
Conclusions FDG uptake by large vessels has a
substantial sensitivity and speciﬁcity for GCA diagnosis.
INTRODUCTION
Temporal artery biopsy is the gold standard for the
diagnosis of giant cell arteritis (GCA) due to the
tropism of GCA for the epicranial arteries.1 2 With
a few exceptions,3 histopathological demonstration
of temporal artery inﬂammation provides the most
deﬁnitive evidence of GCA. Doppler ultrasonog-
raphy (DUS) of temporal arteries has emerged as a
useful alternative tool in centres where biopsy is
not easily available.1
The diagnosis of GCA may be also supported by
demonstrating extracranial artery involvement by
imaging. Over the past recent years, positron emis-
sion tomography/CT (PET/CT), CT angiography,
magnetic resonance imaging (MRI) angiography
and DUS have revealed that extracranial involve-
ment in GCA is more frequent than previously
anticipated, occurring in 30–74% of patients.4–7
PET detection of large-vessel involvement in
patients with fever of unknown origin, unexplained
constitutional symptoms or apparently isolated
polymyalgia rheumatica (PMR) has emphasised its
diagnostic potential.8 9 A limitation of PET as a
diagnostic tool is the lack of a standardised deﬁn-
ition of vascular inﬂammation based on the inten-
sity of 18ﬂuorodeoxyglucose (FDG) uptake. While
visual assessment of intensively positive cases may
be clear, there is no consensus about the minimal
intensity of FDG uptake necessary to deﬁne vascu-
lar inﬂammation. Conversely, atherosclerosis and
ageing may increase vascular FDG uptake, poten-
tially leading to vasculitis overdiagnosis.10
In this study, we measured FDG uptake by differ-
ent vascular territories in a cohort of newly diag-
nosed patients and controls and performed
receiver–operator characteristic curves (ROC) ana-
lysis to determine sensitivity and speciﬁcity of FDG
uptake to detect inﬂammation at different vascular
sites. As a secondary endpoint, we analysed poten-




Between November 2006 and March 2011, all
patients diagnosed with biopsy-proven GCA2 at our
institution were assessed for potential participation
in the study. Patients who had received glucocortic-
oid treatment for >3 days were excluded. Clinical
and laboratory data recorded are detailed in the
online supplementary methods. The study was
approved by the ethics committee (Hospital Clínic,
Barcelona).
The control group included 20 patients with no
chronic inﬂammatory diseases, matched for gender,
age and cardiovascular risk factors (CVRF), con-
secutively selected among patients who underwent
PET/CT during the same timeframe for early lung
cancer staging.
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PET/CT protocol
PET scans were performed using a hybrid PET/CT (Biograph,
Siemens) with an ECAT EXACT HR+BGO PET and a helicoidal
CT scanner (Somatom, Emotion). Patients fasted 4 h before injec-
tion of 370 MBq of 18F-FDG. Whole-body PET data were
acquired 60 min after in three-dimensional mode and for 5 min
per bed position. PET images were reconstructed both with and
without CT data for attenuation correction. A region of interest
(ROI) in 3-D around the vessel was placed manually in transaxial,
sagittal and coronal slices. The standardised uptake value (SUV)
was calculated based on the measured activity, decay-corrected
injected dose and patient body weight. SUVm=maximal activity
(ROI) (mBq/mL)/injected dose (mBq)/weight (g).
Four aortic segments (ascending thoracic aorta, aortic arch,
descending thoracic aorta and abdominal aorta) and the main
tributaries—carotid, subclavian, axillary, iliac and femoral arter-
ies (each bilaterally)—were evaluated. The control group was
subjected to the same PET/CT protocol. Assessment of PET
data was carried out by two nuclear medicine specialists (FL and
MD), who were blinded to clinical and pathological ﬁndings.
However, unequivocal masked evaluation could not be guaran-
teed due to the controls’ disease.
Statistical analysis
ROC were applied to each vascular territory to calculate sensitivity
and speciﬁcity. Area under the curve (AUC) comparison was per-
formed by Hanley and McNeil analysis. Cut-offs with best sensitiv-
ity and speciﬁcity were selected. Mann–Whitney U test or Student t
test, when applicable, were used for quantitative data. Correlations
were calculated using Pearson’s or Spearman’s test. Statistical signiﬁ-
cance was deﬁned as p<0.05. Calculations were performed with
the IBM SPSS Statistics (V.20.0, Armonk, New York, USA).
RESULTS
Clinical and laboratory ﬁndings of the GCA cohort
Seventy-one GCA patients were diagnosed during the recruit-
ment period. Eight patients refused participation, and 31 had
received glucocorticoid treatment for >3 days. The remaining
32 were included. Seventeen of them had been treated for
≤3 days at the time of imaging. Treatment consisted of oral
prednisone at 1 mg/kg/day. Two patients received 250 mg intra-
venous methylprednisolone pulses (1 and 7 pulses, respectively)
due to severe cranial ischaemic symptoms.
Online supplementary table S1 shows the clinical and labora-
tory data of the study group. There were no relevant differences
in age, gender or CVRF between patients and controls (see
online supplementary table S2).
FDG uptake cut-off for GCA diagnosis
SUVm at any vascular territory explored was signiﬁcantly higher
in GCA patients than in controls (table 1). ROC curves and
AUCs are displayed in ﬁgure 1 and table 1, respectively. Mean
of the SUVm observed at all the vascular territories had an AUC
of 0.830 (0.715–0.946). A cut-off of 1.89 had a sensitivity of
80% and a speciﬁcity of 79%. Mean of the SUVm at supraaortic
vessels showed the highest AUC (0.832). In this site, a cut-off of
1.70 achieved a sensitivity and speciﬁcity of 81 and 79%,
respectively, for the diagnosis of GCA (95% CI 0.720 to 0.946).
FDG uptake at the aorta showed lower AUC (0.738), with a
sensitivity and speciﬁcity of 90 and 42, respectively, using a
cut-off of 2.25, and a sensitivity of 58%, speciﬁcity of 90%
with a cut-off of 2.65 (95% CI 0.598 to 0.881). However, dif-
ferences in AUCs among territories did not reach statistical
signiﬁcance.
Vascular/liver uptake ratios were also signiﬁcantly higher in
patients than in controls at the right axillary and carotid arteries,
Table 1 SUVm and AUC at each vascular bed assessed
Territory GCA patients (mean±SD) Controls (mean±SD) p Value AUC (95% CI)
Ascending aorta 2.63±0.57 2.17±0.26 <0.001 0.778 (0.651 to 0.904)
Aortic arch 2.61±0.50 2.23±0.31 0.002 0.756 (0.621 to 0.891)
Descending thoracic aorta 2.78±0.65 2.39±0.33 0.007 0.739 (0.598 to 0.881)
Abdominal aorta 2.97±0.60 2.56±0.39 0.005 0.748 (0.608 to 0.888)
Right subclavian artery 2.46±0.54 2.14±0.40 0.030 0.763 (0.607 to 0.889)
Left subclavian artery 2.26±0.56 1.89±0.28 0.003 0.764 (0.610 to 0.891)
Right carotid artery 2.33±0.52 1.83±0.25 <0.001 0.812 (0.695 to 0.930)
Left carotid artery 2.32±0.51 1.97±0.30 0.004 0.733 (0.594 to 0.872)
Right axillary artery 1.21±0.31 0.88±0.17 <0.001 0.830 (0.725 to 0.940)
Left axillary artery 1.09±0.34 0.88±0.18 0.001 0.780 (0.627 to 0.886)
Right iliac artery 2.41±0.67 2.01±0.38 0.009 0.747 (0.606 to 0.888)
Left iliac artery 2.46±0.47 2.00±0.41 0.002 0.767 (0.628 to 0.905)
Right femoral artery 1.68±0.39 1.24±0.22 <0.001 0.817 (0.715 to 0.928)
Left femoral artery 1.50±0.37 1.14±0.18 <0.001 0.801 (0.679 to 0.922)
All territories* 2.15±0.37 1.79±0.17 <0.001 0.830 (0.715 to 0.946)
Aorta** 2.75±0.54 2.34±0.23 0.001 0.738 (0.612 to 0.874)
Supraaortic branches** 1.95±0.35 1.59±0.15 <0.001 0.832 (0.732 to 0.968)
Iliofemoral territory** 1.97±0.36 1.62±0.23 <0.001 0.802 (0.679 to 0.925)
Liver 2.76±0.57 2.52±0.42 0.119 0.635 (0.480 to 0.790)
Removal of the two patients who had received intravenous methylprednisolone pulses at the time of PET performance did not significantly modify the results (data not shown).
Differences in AUCs among different vascular territories did not reach statistical significance.
AUC, area under the curve; GCA, giant cell arteritis; PET, positron emission tomography.
*Values represent the mean of the SUVm observed at all the vascular beds assessed.
**Aorta, Supraaortic branches and Iliofemoral territory represents the mean of the SUVm observed at the different vessels of these areas.
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but the overall discriminatory performance was much lower (see
online supplementary table S3).
Relationship between FDG uptake and clinical
and laboratory ﬁndings
Patients with cranial symptoms presented signiﬁcantly higher
values of maximal and mean SUVm (combined average of all vas-
cular territories) than patients lacking cranial manifestations. No
relationship between the intensity of FDG uptake and other clin-
ical ﬁndings was observed (table 2). No differences in maximal
or mean SUVm were observed between treatment-naïve patients
and those who had received glucocorticoids. The maximal and
mean SUVm correlated with acute-phase reactants and serum
IL-6 concentrations (table 2).
DISCUSSION
The present prospective study, performed in an unselected
patient cohort with unequivocal GCA, shows that FDG uptake is
signiﬁcantly stronger in patients than in controls in all vascular
territories tested, conﬁrming the diagnostic potential of PET/
CT.4 8 9 11 PET/CTallows rapid, reproducible and broad vascular
evaluation. Nevertheless, there is no standardised deﬁnition of
vasculitis based on an objective FDG uptake measure, and strat-
egies employed to establish a PET-based diagnosis of GCA has
been heterogeneous. Most studies have used qualitative visual
assessment or a semiquantitative score using liver uptake as a ref-
erence. Visual scoring has a remarkable investigator dependency
and interobserver variability. Liver uptake is inﬂuenced by indi-
vidual metabolic activity, glucocorticoid treatment and the time
lapse between injection and scanning.12
We tried to overcome this limitation by objectively quantifying
FDG uptake by different vascular beds in patients and controls
and performing ROC analysis to determine the optimal cut-off
for GCA diagnosis at different vascular territories. FDG uptake
by supraaortic branches had the highest AUC, in accordance with
a pioneer study showing that supraaortic branches were the most
frequently involved when assessed by PET.4 In this area, an FDG
uptake cut-off value of 1.70 had the best sensitivity and speciﬁ-
city. A similar value, in the same territory but with lower per-
formance (AUC=0.72), was reported in a retrospective study of
17 patients with GCA and 3 Takayasu arteritis patients.13 This
observation may be useful to differentiate GCA from other
inﬂammatory aortic diseases that may produce systemic com-
plaints and active aortic FDG uptake, including idiopathic aorti-
tis, periaortitis, IgG4 disease and severe atherosclerosis.10 14–17
This is crucial since a positive PET/CT may be accepted in the
near future as a diagnostic criterion and is currently accepted as
such in an ongoing clinical trial with tocilizumab in GCA.18
Figure 1 Receiver–operator characteristic curves of standardised uptake value at different vascular regions.
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The sensitivity and speciﬁcity of PET/CT obtained in this
study is close to that calculated in a recent systematic review/
meta-analysis of heterogeneous, mostly retrospective studies,
and those reported in a retrospective analysis evaluating the
impact of PET on the management of patients with suspected
large-vessel vasculitis.19
Interestingly, FDG uptake by the aorta showed a lower AUC,
being worse in the abdominal segment where atherosclerosis is
more prevalent in the general population. This fact highlights
the diagnostic limitation of PET in this territory since aortic
FDG uptake may be markedly inﬂuenced by ageing or atheroma
plaques. Hautzel et al reported a higher sensitivity and speciﬁ-
city of thoracic aorta FDG uptake to detect large-vessel inﬂam-
mation in a cohort of 18 patients with GCA.20 A thoracic aorta/
liver ratio of 1.0 had a sensitivity and speciﬁcity of 88% and
93%, respectively (AUC = 0.932). However, a substantial pro-
portion of the patients assembled in this cohort were selected
on the basis of previously known large-vessel involvement
demonstrated by other techniques. In our study, direct, territory-
focused comparison of SUVm between patients and controls dis-
criminated better than vascular/liver ratios.
A retrospective study evaluating how PET/CT results inﬂu-
enced management of patients with suspected GCA suggested
that previous glucocorticoid (GC) treatment decreased the diag-
nostic yield of PET/CT.19 Sequential assessments have demon-
strated, indeed, that FDG uptake decreases after 3 months of
treatment.4 The present study suggests that a short course of
therapy (≤3 days) may not substantially reduce the diagnostic
accuracy of PET/CT.
In conclusion, this study provides sensitive and speciﬁc,
territory-focused cut-off values to detect vascular inﬂammation
by PET/CT. A limitation of the study is that while patients were
prospectively recruited, controls were retrospectively selected.
Another limitation is the relatively small number of patients ana-
lysed, although our cohort is among the largest investigated.
Further prospective studies using objective cut-offs are necessary
to conﬁrm their diagnostic performance in patients with sus-
pected GCA.
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